# WAY earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/WAY) · [Earnings tab](https://www.lopjlb.com/stock/WAY?tab=earnings)

Updated: 2026-07-29T06:24:38

Quarters analyzed: 7

## Cross-quarter narrative

Across six earnings cycles Waystar transitioned from a recovery phase marked by modest revenue growth and vague guidance (Q3 2024) to a high‑growth, AI‑centric trajectory by Q1 2026. Revenue accelerated from $240 M to $314 M YoY, while adjusted EBITDA margins rose from ~40 % to 43 %, reflecting higher‑margin AI solutions and cost initiatives. The AltitudeAI platform debuted in Q4 2024 and expanded into broader AI‑driven demand, now accounting for roughly 40 % of new bookings. The Iodine acquisition, announced in Q2 2025 and delivered in Q3 2025, added a new product layer, though integration timelines of 18‑24 months temper near‑term synergies. Deleveraging remained a priority, with net leverage improving from 2.8× to around 2.2× and cash generation strengthening. Persistent concerns include regulatory shifts, utilization volatility, and cybersecurity, all recurring across calls. New risks emerged around AI adoption preferences, Iodine revenue pacing, and patient‑statement digitization delays. Overall, Waystar’s growth narrative is one of accelerating top‑line and margin expansion powered by AI and strategic M&A, balanced against ongoing integration and macro‑environmental uncertainties.

## Latest CallCard · Q1

Waystar Q1 2026: 22% YoY revenue growth to $314M, 43% adj. EBITDA margin, AI driving 40% of new bookings, net revenue retention 111%, Iodine integration ahead of plan, new AI recruitment solution launched, largest pipeline ever supporting visibility into 2027.','tone':{'mgmt':0.7,'mgmt_rationale':'M

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Waystar Q1 2026: 22% YoY revenue growth to $314M, 43% adj. EBITDA margin, AI driving 40% of new bookings, net revenue retention 111%, Iodine integration ahead of plan, new AI recruitment solution launched, largest pipeline ever supporting visibility into 2027.','tone':{'mgmt':0.7,'mgmt_rationale':'M
- **2025 Q4:** Waystar posted strong Q4 2025 results, beating revenue and EBITDA guidance, highlighted AI leadership and Iodine integration, and reaffirmed 2026 growth guidance amid moderate analyst questions on AI adoption and margin synergies.
- **2025 Q3:** Waystar posted double‑digit Q3 revenue growth, 42% EBITDA margin and raised full‑year guidance, highlighting Iodine acquisition benefits while noting integration timelines and margin pressure.
- **2025 Q2:** Waystar Q2 revenue $271M (+15% YoY), adj EBITDA margin 42%; raised FY guidance; announced $1.25B Iodine acquisition; strong AI-driven demand, net retention 115%.
- **2025 Q1:** —
- **2024 Q4:** Waystar Q4 2024: revenue $244M (+18% YoY), FY $944M (+19%), adj. EBITDA margin 40.6%; 2025 guidance $1.0-1.16B revenue (7% reported, 10% normalized), adj. EBITDA $399-407M (40% margin); NRR 110%, 30% of cyber-impacted clients pursuing cross-sell; launched AltitudeAI generative AI. Debt repriced, lev
- **2024 Q3:** Waystar Q3 revenue $240M (+22% YoY), adj. EBITDA $97M (40% margin); raised FY24 guidance to $926-934M revenue, $374-378M EBITDA; 2025 revenue seen approaching $1B; benefited from competitor cyber event onboarding 30k+ providers; generative AI launches planned 2025.','tone': {'mgmt': 0.8, 'mgmt_ratio

## Theme arcs

- **Revenue growth** (improving): YoY revenue rose from $240M in Q3 2024 to $314M in Q1 2026, with guidance moving toward $1B+
- **EBITDA margin expansion** (improving): Margins climbed from ~40 % to 43 % as AI mix improved
- **AI‑driven demand** (improving): AltitudeAI launch and AI‑powered bookings now drive ~40 % of new revenue
- **Iodine acquisition impact** (new): Acquired in Q2 2025, delivered Q3 2025, early revenue contribution but integration extends 18‑24 months
- **Deleveraging focus** (improving): Net leverage fell from 2.8× to ~2.2×, cash generation strong
- **Integration risk** (deteriorating): HealthPay/Olive AI and Iodine integrations repeatedly cited as timeline challenges
- **Utilization volatility** (deteriorating): Volume normalization and patient utilization assumptions remain uncertain
- **Cross‑sell conversion** (resolved): Early concern about low cross‑sell rates faded after Q4 2024
- **Regulatory risk** (stable): Policy changes and compliance risk cited in multiple quarters
- **Cybersecurity risk** (stable): Competitor breach highlighted systemic risk across calls

## Fear persistence

- **Regulatory/compliance risk** [recurring]: Policy changes noted Q4 2024; regulatory risk reiterated Q4 2025
- **Utilization volatility** [recurring]: Volume normalization Q4 2024; utilization volatility Q3 2025; patient utilization assumptions Q4 2025

## Guidance path

2024 Q3:vague → 2024 Q4:raised → 2025 Q1:vague → 2025 Q2:raised → 2025 Q3:raised → 2025 Q4:maintained → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/WAY`